Related Articles
19 January 2023
9 March 2021
NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the close of a £15.2m (US $21m) Series B round. The syndicate was led by Claris Ventures and included 2Invest, 3B Future Health Fund and Astellas Venture Management alongside founding investor the CRT Pioneer Fund.
Get in touch
Thank you for your form submission, we will get in contact with you shortly.
